CN105816920B - 一种改性海藻酸钠栓塞微球的制备方法 - Google Patents
一种改性海藻酸钠栓塞微球的制备方法 Download PDFInfo
- Publication number
- CN105816920B CN105816920B CN201610188793.3A CN201610188793A CN105816920B CN 105816920 B CN105816920 B CN 105816920B CN 201610188793 A CN201610188793 A CN 201610188793A CN 105816920 B CN105816920 B CN 105816920B
- Authority
- CN
- China
- Prior art keywords
- sodium alginate
- embolism microball
- modified sodium
- modified
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical class CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 208000005189 Embolism Diseases 0.000 title claims abstract description 74
- 239000011806 microball Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 43
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 35
- 239000000661 sodium alginate Substances 0.000 claims abstract description 33
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 33
- 229960003080 taurine Drugs 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 125000000542 sulfonic acid group Chemical group 0.000 claims abstract description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- 238000004945 emulsification Methods 0.000 claims abstract description 4
- 239000002480 mineral oil Substances 0.000 claims abstract description 4
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 5
- 238000011938 amidation process Methods 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 229940009456 adriamycin Drugs 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- 241000736199 Paeonia Species 0.000 claims description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000012047 saturated solution Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 2
- 239000003921 oil Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000002386 leaching Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000010109 chemoembolization Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- -1 amine salt Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000002801 charged material Substances 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610188793.3A CN105816920B (zh) | 2016-03-29 | 2016-03-29 | 一种改性海藻酸钠栓塞微球的制备方法 |
PCT/CN2017/071080 WO2017166903A1 (zh) | 2016-03-29 | 2017-01-13 | 一种改性海藻酸钠栓塞微球的制备方法 |
US15/756,021 US20190008775A1 (en) | 2016-03-29 | 2017-01-13 | Method for Preparing Modified Sodium Alginate Embolization Microsphere |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610188793.3A CN105816920B (zh) | 2016-03-29 | 2016-03-29 | 一种改性海藻酸钠栓塞微球的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105816920A CN105816920A (zh) | 2016-08-03 |
CN105816920B true CN105816920B (zh) | 2018-10-23 |
Family
ID=56525335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610188793.3A Active CN105816920B (zh) | 2016-03-29 | 2016-03-29 | 一种改性海藻酸钠栓塞微球的制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20190008775A1 (zh) |
CN (1) | CN105816920B (zh) |
WO (1) | WO2017166903A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105816920B (zh) * | 2016-03-29 | 2018-10-23 | 江南大学 | 一种改性海藻酸钠栓塞微球的制备方法 |
CN108636374B (zh) * | 2018-06-06 | 2020-02-18 | 四川大学 | 一种多巴胺接枝磺化海藻酸钠双交联微球及其制备方法和用途 |
CN110106728B (zh) * | 2019-05-08 | 2021-10-26 | 安徽省翰先纺织科技有限公司 | 涂料印花工艺 |
CN110327284B (zh) * | 2019-07-18 | 2022-11-22 | 石药集团中诺药业(石家庄)有限公司 | 一种注射用头孢地嗪钠及其制备方法 |
CN111481734B (zh) * | 2020-04-28 | 2022-04-15 | 北京诺康达医药科技股份有限公司 | 一种改性海藻酸钠自显影栓塞微球及其制备方法与应用 |
CN112300418B (zh) * | 2020-09-24 | 2022-04-26 | 山东百多安医疗器械股份有限公司 | 一种可粘附高效止血微球及其制备方法 |
CN112369414A (zh) * | 2020-11-18 | 2021-02-19 | 方明东 | 一种磁性除虫菊酯复合载药微球的制备方法 |
CN113730646A (zh) * | 2021-08-27 | 2021-12-03 | 中国海洋大学 | 一种高载药可降解褐藻酸硫酸酯血管栓塞微球及其制备方法和应用 |
CN115245592A (zh) * | 2022-01-06 | 2022-10-28 | 青岛大学 | 一种发光显影二合一明胶栓塞微球及其制备方法 |
CN114404366B (zh) * | 2022-02-17 | 2023-12-15 | 深圳玉莱漫生物科技有限公司 | 苦参总碱透皮吸收纳米微乳 |
CN115282933B (zh) * | 2022-06-28 | 2024-07-19 | 武汉工程大学 | 一种氨基磺酸盐改性海藻酸钠吸附剂及其制备方法和应用 |
CN115591006A (zh) * | 2022-09-14 | 2023-01-13 | 苏州大学(Cn) | 天然抗菌的茶多酚-丝素/壳聚糖栓塞微球及其制备方法 |
CN115634314B (zh) * | 2022-10-28 | 2023-08-04 | 广州贝奥吉因生物科技股份有限公司 | 一种非支撑骨修复凝胶微球及其制备方法 |
CN116617445B (zh) * | 2023-07-26 | 2023-10-17 | 海杰亚(北京)医疗器械有限公司 | 一种可生物降解的栓塞微球及其制备方法和应用 |
CN117323294B (zh) * | 2023-09-25 | 2024-05-31 | 至微(深圳)医学科技有限公司 | 一种载药栓塞微球及其制备方法和应用 |
CN117815434B (zh) * | 2024-03-05 | 2024-05-24 | 山东第二医科大学 | 一种氧化再生纤维素栓塞微球及其制备方法 |
CN117838913B (zh) * | 2024-03-06 | 2024-05-24 | 山东第二医科大学 | 一种莪术油/氧化再生纤维素栓塞微球及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2401879A1 (en) * | 2000-03-06 | 2001-09-13 | Stephan Mangin | Embolic agents visible under ultrasound |
WO2012003704A1 (zh) * | 2010-07-09 | 2012-01-12 | 北京圣医耀科技发展有限责任公司 | 海藻酸钠交联莫西沙星缓释微球、其制备方法和用途以及含有所述微球的血管靶向栓塞剂 |
CN104258474A (zh) * | 2014-10-15 | 2015-01-07 | 江南大学 | 一种含有离子交换功能基团的栓塞微球 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100518719C (zh) * | 2006-07-05 | 2009-07-29 | 中国科学院大连化学物理研究所 | 一种复合基质的多功能动脉栓塞剂的制备方法 |
CN101058058B (zh) * | 2007-05-23 | 2010-08-11 | 中国科学院上海有机化学研究所 | 一种表面固定牛磺酸配基的多孔膜材料、制备方法及其在血脂吸附分离中的应用 |
US8168224B2 (en) * | 2007-12-19 | 2012-05-01 | Beijing Shengyiyao Science & Technology Development Co., Ltd. | Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof |
JP5957610B2 (ja) * | 2012-08-31 | 2016-07-27 | チュンアン ユニバーシティー インダストリー アカデミック コアポレイション ファウンデイション | 塞栓用のミクロスフェアの製造方法及び薬物含有ナノ輸送体が結合されたミクロスフェアの製造方法 |
CN105816920B (zh) * | 2016-03-29 | 2018-10-23 | 江南大学 | 一种改性海藻酸钠栓塞微球的制备方法 |
-
2016
- 2016-03-29 CN CN201610188793.3A patent/CN105816920B/zh active Active
-
2017
- 2017-01-13 WO PCT/CN2017/071080 patent/WO2017166903A1/zh active Application Filing
- 2017-01-13 US US15/756,021 patent/US20190008775A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2401879A1 (en) * | 2000-03-06 | 2001-09-13 | Stephan Mangin | Embolic agents visible under ultrasound |
WO2012003704A1 (zh) * | 2010-07-09 | 2012-01-12 | 北京圣医耀科技发展有限责任公司 | 海藻酸钠交联莫西沙星缓释微球、其制备方法和用途以及含有所述微球的血管靶向栓塞剂 |
CN104258474A (zh) * | 2014-10-15 | 2015-01-07 | 江南大学 | 一种含有离子交换功能基团的栓塞微球 |
Non-Patent Citations (2)
Title |
---|
Alginate droplets pre-crosslinked in microchannels to prepare monodispersed spherical microgels;Qin Wang et al;《Colloids and Surfaces A:Physicochem. Eng. Aspects》;20150627;第482卷;371-377 * |
海藻酸钠微球栓塞剂在肿瘤治疗中的应用现状;孙伟 等;《癌症进展杂志》;20090131;第7卷(第1期);52-55 * |
Also Published As
Publication number | Publication date |
---|---|
US20190008775A1 (en) | 2019-01-10 |
CN105816920A (zh) | 2016-08-03 |
WO2017166903A1 (zh) | 2017-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105816920B (zh) | 一种改性海藻酸钠栓塞微球的制备方法 | |
CN106110334B (zh) | 一种表面功能化可载药洗脱微球的制备方法 | |
US20210093607A1 (en) | Antitumor nano-drug | |
CN104530256B (zh) | 透明质酸维生素e琥珀酸酯聚合物及其制备和用途 | |
CN102085177B (zh) | 一种可还原降解纳米载药胶束及其制备方法 | |
KR102237234B1 (ko) | 간 표적성을 갖는 유전자/약물을 공동으로 운반하는 통합식 나노 시스템 및 이의 제조 방법 | |
CN106139144A (zh) | 一种具有协同抗肿瘤特性的透明质酸修饰的金‑碳纳米球及其制备方法与应用 | |
AU2012305327A1 (en) | Polymer-type fluorescent molecule probe | |
An et al. | Rosin-based block copolymer intracellular delivery nanocarriers with reduction-responsive sheddable coronas for cancer therapy | |
CN106693040A (zh) | 一种可载药聚乙烯醇洗脱微球的制备方法 | |
CN102631679A (zh) | pH敏感普鲁兰多糖衍生物纳米药物载体和载药粒子及制备方法 | |
CN108653747B (zh) | 一种基因与疏水药物共输送的可降解纳米载体及其制法和应用 | |
CN107158410B (zh) | 一种具有肿瘤靶向性的叶酸-壳聚糖-Cy7聚合物及其制备方法 | |
CN105859990B (zh) | 侧链含硫辛酰基的聚合物、其制备方法及由其制备的聚合物囊泡及其应用 | |
CN101658484B (zh) | 胆固醇甲酰氯修饰的壳聚糖共聚物载药胶束的制备方法和应用 | |
CN110237264A (zh) | 一种包载盐酸阿霉素的TA-Fe(III)修饰的PLGA纳米颗粒及其制备方法 | |
CN105395483A (zh) | 一种可还原降解超支化聚合物纳米胶束及其制备方法 | |
Peng et al. | Nanogels loading curcumin in situ through microemulsion photopolymerization for enhancement of antitumor effects | |
Zhang et al. | Reactive oxygen species-activatable camptothecin polyprodrug based dextran enhances chemotherapy efficacy by damaging mitochondria | |
CN108339124A (zh) | 一种双级脑靶向聚合物胶束递药***的制备方法和应用 | |
CN111333786A (zh) | 基于两性离子及叶酸靶向的酸敏感性阿霉素前药的制备方法 | |
CN104761732A (zh) | 一种肿瘤细胞靶向的纳米凝胶及其制备方法以及一种肿瘤细胞靶向的纳米凝胶载药颗粒 | |
Huang et al. | Antitumor activity and antitumor mechanism of triphenylphosphonium chitosan against liver carcinoma | |
CN105330794A (zh) | 具有主动-被动双重靶向抗肿瘤活性的两亲性嵌段共聚物及其制备和应用 | |
CN115845059A (zh) | 一种基于聚氨基酸的小分子抑制剂纳米粒及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221117 Address after: Room 501, 85 Xiaguang Dongli, Haicang District, Xiamen City, Fujian Province, 361000 Patentee after: Xiamen reliable intellectual property service Co.,Ltd. Address before: No. 1800 road 214122 Jiangsu Lihu Binhu District City of Wuxi Province Patentee before: Jiangnan University Effective date of registration: 20221117 Address after: No. 8, Longquanhe 5th Road, Qingdao North Industrial Park, Jimo, Qingdao, Shandong 266000 Patentee after: QINGDAO HYZLIN BIOLOGY DEVELOPMENT Co.,Ltd. Address before: Room 501, 85 Xiaguang Dongli, Haicang District, Xiamen City, Fujian Province, 361000 Patentee before: Xiamen reliable intellectual property service Co.,Ltd. |
|
TR01 | Transfer of patent right |